CABA

Cabaletta Bio Inc

2.08

Oct 05 • 3:40 PM ET +0.08 (4.15%)

Healthcare Biotechnology USA Small NASD

Peers: BMRN INCY KRYS KYMR RYTM CRNX VKTX AXSM MDGL NBIX

| Held by: VTI XBI IWM VXF FESM IBB VTWO IWO IWN SURI

Index	RUT
Market Cap	353.15M
Enterprise Value	153.76M
Income	-181.32M
Sales	0.00M
Book/sh	1.26
Cash/sh	1.33
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	156
IPO	Oct 25, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.66
P/C	1.57
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	5.79
Current Ratio	5.79
Debt/Eq	0.12
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.58
EPS next Y	-1.20
EPS next Q	-0.32
EPS this Y	35.15%
EPS next Y	11.94%
EPS next 5Y	22.07%
EPS past 3/5Y	-5.18% -7.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	41.56%
Sales Y/Y TTM	-
EPS Q/Q	53.72%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	8.82% -

Insider Own	21.49%
Insider Trans	0.00%
Inst Own	82.94%
Inst Trans	69.65%
ROA	-75.36%
ROE	-93.20%
ROIC	-83.63%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-13.31%
SMA50	-24.18%
SMA200	-28.46%
Trades

Shs Outstand	167.73M
Shs Float	133.12M
Short Float	25.03%
Short Ratio	6.87
Short Interest	33.33M
52W High	4.23 -50.76%
52W Low	1.83 13.82%
Volatility	6.04% 7.85%
ATR (14)	0.18
RSI (14)	35.70
Beta	3.53
Rel Volume	0.83
Avg Volume	4.85M
Volume	3,825,686

Perf Week	4.15%
Perf Month	-40.15%
Perf Quarter	-32.81%
Perf Half Y	-30.80%
Perf YTD	-4.89%
Perf Year	-14.64%
Perf 3Y	-85.56%
Perf 5Y	-81.55%
Perf 10Y	-
Recom	1.40
Target Price	13.25
Prev Close	2.00
Price	2.08
Change %	4.15%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-25	Resumed	Jefferies	Buy	$14
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$15 → $6
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12 → $6
Oct-10-24	Initiated	UBS	Buy	$10
Feb-05-24	Initiated	Jefferies	Buy	$36
Nov-29-23	Initiated	William Blair	Outperform	$38
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$40
Oct-19-23	Initiated	Stifel	Buy	$31
Sep-05-23	Initiated	Citigroup	Buy	$22
Jul-18-23	Initiated	Guggenheim	Buy	$34
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$3 → $16
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $3
Dec-08-21	Initiated	Wells Fargo	Overweight	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$20
Jun-30-21	Initiated	Mizuho	Buy	$22
Jan-08-21	Initiated	Chardan Capital Markets	Buy	$21
Oct-13-20	Initiated	H.C. Wainwright	Buy	$20
Nov-19-19	Initiated	Morgan Stanley	Overweight	$19
Nov-19-19	Initiated	Evercore ISI	Outperform	$25
Nov-19-19	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-02-26 08:32AM	Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts (BioPharma Dive) +8.18%
Sep-01-26 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.11%
Aug-13-26 07:30AM	Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jun-09-26 05:19PM	FDA Clears Imvivas Dual-Target CAR-T for Autoimmune Diseases (Exec Edge) -5.59%
Jun-03-26 07:00AM	Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress (GlobeNewswire)
07:05AM	Loading…
May-14-26 07:05AM	Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting (GlobeNewswire)
May-04-26 06:35AM	Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering (GlobeNewswire) +30.27%
Apr-28-26 08:00AM	Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel (Business Wire)
08:00AM	Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel (GlobeNewswire)
Apr-27-26 05:00PM	Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting (GlobeNewswire)
Apr-14-26 04:30PM	First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform (Business Wire)
Mar-27-26 01:11PM	This Biotech Stock Could Deliver 350% Returns in 12 Months (GuruFocus.com)
Mar-23-26 07:30AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-07-26 05:46AM	Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference (MarketBeat)
12:00PM	Loading…
Mar-06-26 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-03-26 09:40AM	Are Medical Stocks Lagging Biodesix (BDSX) This Year? (Zacks)
Feb-24-26 08:00AM	Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +13.45%
Feb-18-26 08:34AM	Here's Why Jacob Funds Established a Position in Cabaletta Bio (CABA) (Insider Monkey) +5.74%
Feb-13-26 12:07AM	Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA (MarketBeat)
Feb-12-26 09:40AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? (Zacks) +10.89%
Feb-05-26 08:00AM	Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.17%
Jan-30-26 12:00PM	What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now? (Zacks) -6.55%
Jan-27-26 09:40AM	Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-12-26 08:00AM	Cabaletta Bio Announces 2026 Strategic Priorities (GlobeNewswire) +5.24%
07:30AM	IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms (Business Wire)
Nov-10-25 07:30AM	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks) -10.30%
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December (GlobeNewswire)
Oct-31-25 05:42AM	Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials (Insider Monkey) +46.15%
07:00AM	Loading…
Oct-27-25 07:00AM	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 (GlobeNewswire) +12.96%
Oct-14-25 08:00AM	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant (GlobeNewswire) +16.06%
Oct-09-25 12:00PM	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress (GlobeNewswire) +18.26%
Aug-27-25 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-11-25 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's Why (Zacks)
Aug-07-25 07:30AM	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 09:54AM	Cabaletta Bio Announces Pricing of Public Offering of Securities (GlobeNewswire) -25.53%
06:15AM	Cabaletta Bio Announces Proposed Public Offering of Securities (GlobeNewswire)
06:00AM	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress (GlobeNewswire)
May-29-25 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-15-25 07:00AM	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts (GlobeNewswire) +39.23%
Apr-01-25 12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks) -15.52%
Mar-31-25 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.65%
Mar-19-25 07:00AM	Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform (Business Wire) +6.59%
Feb-26-25 08:00AM	Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 10:21AM	UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire) -14.02%
07:00AM	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire)
Feb-11-25 08:00AM	Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February (GlobeNewswire)
Jan-29-25 08:00AM	Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 (GlobeNewswire)
Nov-26-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in December (GlobeNewswire) +5.68%
Nov-18-24 07:00AM	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 (GlobeNewswire) -10.89%
Nov-14-24 07:00AM	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.74%
Nov-06-24 08:00AM	Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire) +10.71%
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings (GuruFocus.com)
Sep-25-24 04:30PM	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:32AM	Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 (Insider Monkey) +20.65%
Aug-08-24 07:00AM	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -34.37%
Jul-08-24 07:01PM	Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now? (Insider Monkey) +7.23%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum (GlobeNewswire) -5.38%
Jun-14-24 02:00AM	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201 (GlobeNewswire) -15.13%
May-29-24 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -5.81%
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-15-24 11:54AM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 (InvestorPlace) +13.00%
07:00AM	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-23-24 05:31AM	Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway (GuruFocus.com)
Mar-21-24 01:53PM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:00AM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis (GlobeNewswire)
Mar-08-24 08:50AM	Jim Cramer's 10 Latest Stock Picks This Week (Insider Monkey)
Feb-27-24 10:11AM	Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 (Insider Monkey)
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-01-24 04:30PM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis (GlobeNewswire) +7.05%
Jan-31-24 08:00AM	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:00AM	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis (GlobeNewswire) +8.70%
Jan-02-24 08:00AM	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:49PM	Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally (TipRanks) +7.14%
Nov-28-23 04:30PM	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -26.79%
Nov-09-23 08:10AM	Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
07:00AM	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:15AM	Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabalettas CD19-CAR T Cell Therapy on Cellares Cell Shuttle Platform (Business Wire)
07:00AM	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis (GlobeNewswire)
Oct-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November (GlobeNewswire) +7.50%
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks) +5.70%
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks)
07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 (GlobeNewswire)
Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-25-23 08:50AM	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing' (Zacks)
Sep-19-23 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire) -6.92%
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -5.93%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:55AM	Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade (Zacks)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-23 10:13AM	Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment (American City Business Journals)
Aug-23-23 08:50AM	Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why (Zacks)

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

MDSteven Nichtberger

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chang David J.	Chief Medical Officer	Jan 21 '26	Buy	2.26	8,800	19,888	8,800	Jan 21 06:56 PM
Binder Gwendolyn	President, Science & Tech.	Jan 21 '26	Buy	2.19	11,312	24,763	31,312	Jan 21 06:56 PM
Tomasello Shawn	Director	Jan 21 '26	Buy	2.21	22,725	50,322	22,725	Jan 21 06:55 PM
Gavel Steve	Chief Commercial Officer	Jan 21 '26	Buy	2.27	22,170	50,215	22,170	Jan 21 06:55 PM
Bollard Catherine	Director	Jan 21 '26	Buy	2.27	4,405	9,982	5,405	Jan 21 06:54 PM
Nichtberger Steven	President & CEO	Jan 21 '26	Buy	2.24	45,000	100,778	1,031,483	Jan 21 06:54 PM
Simon Mark	Director	Jan 21 '26	Buy	2.28	11,061	25,261	147,205	Jan 21 06:53 PM
Gerard Michael	General Counsel	Jan 21 '26	Buy	2.27	6,600	14,979	6,600	Jan 21 06:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CABA

Cabaletta Bio Inc

Upgrade your Finviz experience